Five things for pharma marketers to know for Monday, February 23, 2026 - MMM Online
The FDA is reviewing the safety of SSRIs and RSV antibodies for infants due to concerns about current monitoring. The Supreme Court invalidated Trump's tariffs, potentially reducing supply chain costs. Novo Nordisk lowered its 2026 sales and profit forecasts amid rising competition in the GLP-1 market. Additionally, the CDC's vaccine advisory meeting was postponed as HHS Secretary Kennedy works to reshape vaccine policies, and an Alzheimer’s blood test shows promise but is not yet ready for widespread use.
Top FDA drug regulator to scrutinize SSRIs and RSV antibodies for infants. Tracy Beth Høeg told her staff that she believes safety monitoring for both products is inadequate right now. (STAT)
*SCOTUS knocks down Trump’s tariffs. *The Supreme Court ruled that former President Donald Trump overstepped his authority in imposing sweeping global tariffs, a decision that could ease cost pressures across supply chains, including for pharmaceuticals. (Reuters)
Novo Nordisk trims its outlook. The drugmaker warned that sales and operating profit could decline in 2026 as competition intensifies in the booming GLP-1 market. (Reuters)
*Another shakeup for the CDC’s vaccine advisers. *HHS postponed a key meeting as Secretary Robert F. Kennedy Jr. moves to reshape federal vaccine policy. (Axios)
Alzheimer’s blood test could soon predict symptom onset. The test uses Alzheimer’s biomarkers to model how long it will take for symptoms to appear, but scientists warn it’s not ready for mainstream use quite yet.* *(Scientific American)
To read last week’s Five things for pharma marketers to know, click here.
Comments (0)
No comments yet. Be the first to share your thoughts.
Sign in to leave a comment.